Novel GPCR paradigms at the μ-opioid receptor

Georgina Louise Thompson, Eamon Kelly, Arthur Christopoulos, Meritxell Canals

Research output: Contribution to journalArticleResearchpeer-review

52 Citations (Scopus)


Opioids, such as morphine, are the most clinically useful class of analgesic drugs for the treatment of acute and chronic pain. However, the use of opioids is greatly limited by the development of severe adverse side effects. Consequently, drug discovery efforts have been directed towards improving the therapeutic profile of opioid-based treatments. Opioid receptors are members of the family of GPCRs. As such, the recent GPCR paradigms of biased agonism and allosterism may provide novel avenues for more effective analgesics. Biased agonism (or functional selectivity) has been described for all the opioid receptor family members. Furthermore, the first allosteric modulators of opioid receptors have very recently been described. However, identification and quantification of biased agonism in a manner that is informative to medicinal chemists and drug discovery programmes still remains a challenge. In this review, we examine the progress, to date, towards identification and quantification of biased agonism and allosterism at the μ-opioid receptor in the context of its implications for the discovery of better and safer analgesics.
Original languageEnglish
Pages (from-to)287-296
Number of pages10
JournalBritish Journal of Pharmacology
Issue number2
Publication statusPublished - 2015


  • allosterism
  • biased-agonism
  • GPCR
  • μ-opioid receptor

Cite this